Insights

Innovative Delivery Platform Code Bio's proprietary 3DNA® platform offers a non-viral, targeted gene delivery system that addresses key challenges in genetic medicine, making it highly attractive to biotech firms seeking safer, more efficient delivery mechanisms for genetic therapies.

Strong Funding and Backing With a recent $75M Series A financing from notable investors including 4BIO Capital and UPMC Enterprises, alongside strategic partnerships like Takeda Pharmaceuticals, Code Bio demonstrates solid financial backing and a proven ability to attract high-profile investment looking for innovative biotech opportunities.

Focused Oncology and Rare Disease Programs The company's research pipeline targeting diseases such as Duchenne’s Muscular Dystrophy and potential applications in lung, pancreas, and liver tissues present opportunities to expand collaborations with pharmaceutical companies interested in rare and debilitating genetic diseases.

Leadership and Talent Growth Recent senior-level hires, including a Chief Technical Officer from BridgeBio and a SVP from SwanBio, indicate strategic growth, creating avenues to partner with a team that has deep expertise in gene therapy development and translational research.

Market Trends Alignment As the gene therapy market continues rapid growth with increasing demand for targeted, non-viral delivery systems, Code Bio’s technology positions it as a potential partner or provider for companies looking to innovate in genetic medicine, offering scalable solutions for personalized medicine applications.

Code Biotherapeutics Tech Stack

Code Biotherapeutics uses 8 technology products and services including Wix, Open Graph, Cart Functionality, and more. Explore Code Biotherapeutics's tech stack below.

Wix

Content Management System

Open Graph

Content Management System

Cart Functionality

E-commerce

Wix eCommerce

E-commerce

JSON-LD

Javascript Frameworks

Google Tag Manager

Tag Management

X-Content-Type-Options

Web & Portal Technology

Google Analytics

Web Analytics

Code Biotherapeutics Email Formats	Example	Percentage
FLast@codebiotx.com	JDoe@codebiotx.com	49%
FL@codebiotx.com	JD@codebiotx.com	1%
FirstLast@codebiotx.com	JohnDoe@codebiotx.com	1%
FLast@codebiotx.com	JDoe@codebiotx.com	49%

Code Biotherapeutics Email Formats

Example

Percentage

FLast@codebiotx.com

JDoe@codebiotx.com

49%

FL@codebiotx.com

JD@codebiotx.com

FirstLast@codebiotx.com

JohnDoe@codebiotx.com

FLast@codebiotx.com

JDoe@codebiotx.com

49%

Frequently Asked Questions

Where is Code Biotherapeutics's headquarters located?

Code Biotherapeutics's main headquarters is located at 2801 Sterling Drive Hatfield, Pennsylvania 19440 United States. The company has employees across 1 continents, including North America.

What is Code Biotherapeutics's official website and social media links?

Code Biotherapeutics's official website is codebiotx.com and has social profiles on LinkedIn Crunchbase.

What is Code Biotherapeutics's SIC code NAICS code?

Code Biotherapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Code Biotherapeutics have currently?

As of February 2026, Code Biotherapeutics has approximately 21 employees across 1 continents, including North America. Key team members include Chief Technical Officer: A. T.Chief Scientific Officer: D. A.Chief Platform Technologies Officer: R. G.. Explore Code Biotherapeutics's employee directory with LeadIQ.

What industry does Code Biotherapeutics belong to?

Code Biotherapeutics operates in the Biotechnology Research industry.

What technology does Code Biotherapeutics use?

Code Biotherapeutics's tech stack includes WixOpen GraphCart FunctionalityWix eCommerceJSON-LDGoogle Tag ManagerX-Content-Type-OptionsGoogle Analytics.

What is Code Biotherapeutics's email format?

Code Biotherapeutics's email format typically follows the pattern of FLast@codebiotx.com. Find more Code Biotherapeutics email formats with LeadIQ.

How much funding has Code Biotherapeutics raised to date?

As of February 2026, Code Biotherapeutics has raised $75M in funding. The last funding round occurred on Jun 07, 2022 for $75M.

When was Code Biotherapeutics founded?

Code Biotherapeutics was founded in 2020.

Code Biotherapeutics

Q: What is Code Biotherapeutics's official website and social media links?

Code Biotherapeutics's official website is codebiotx.com. Code Biotherapeutics has social profiles on LinkedIn.

Q: How many employees does Code Biotherapeutics have currently?

Code Biotherapeutics has approximately 21 employees.

Q: What technology does Code Biotherapeutics use?

Code Biotherapeutics's tech stack includes Vimeo, Priority Hints, Office 365, Wix, Bootstrap.

Biotechnology ResearchPennsylvania, United States11-50 Employees

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients.

Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.

The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.

Insights

Similar companies to Code Biotherapeutics

Sarepta Therapeutics

Vertex Pharmaceuticals

Moderna

Editas Medicine

Genentech

Alnylam Pharmaceuticals

bluebird bio

CRISPR Therapeutics

Solid Biosciences

Kite Pharma